Loading...
Loading...
Zimmer Holdings, Inc. (NYSE and
SIX: ZMH) ("Zimmer") announced today that it has proposed a remedy package to
the European Commission (the "EC") to facilitate the EC's approval of Zimmer's
proposed acquisition of Biomet.
Zimmer has been working closely with the EC to develop a mutually-acceptable
solution to address the discrete concerns identified by the EC in its
preliminary assessment of the proposed acquisition of Biomet. The remedy
package proposed by Zimmer includes the divestiture of one unicompartmental
knee brand and one elbow brand in the European Economic Area ("EEA") and one
total knee brand in two EEA countries. The EC will market-test the proposed
remedy package in the coming days. In parallel, the EC has "stopped the
clock" on its review of the proposed merger.
Zimmer continues to be encouraged by the substantial progress that has been
made to date in connection with the overall regulatory process and expects to
close the transaction in the first quarter of 2015.
The transaction also remains subject to the expiration or termination of the
applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, approval from the Japan Fair Trade Commission, as well as other
customary closing conditions.
Under the terms of the merger agreement announced on April 24, 2014, Zimmer
will acquire Biomet in a cash and stock transaction valued at approximately
$13.35 billion, including the assumption of net debt.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in